Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

2015581 citationsJournal Article

Authors

Sai‐Hong Ignatius Ou · Karolinska University Hospital

Jin Seok Ahn · Karolinska University Hospital

Luigi De Petris · Karolinska University Hospital

Ramaswamy Govindan · Karolinska University Hospital

James Chih‐Hsin Yang · Karolinska University Hospital

Brett Hughes · Karolinska University Hospital

H. Léna

Abstract

Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 34, Issue 7, pp. 661-668

DOI: 10.1200/jco.2015.63.9443

Field-Weighted Citation Impact: 80.36